Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine vs Aprepitant for CINV Prophylaxis
NCT03478605Phase 2Unknown
- Sponsor
- N.N. Blokhin Russian Cancer Research Center
- Start
- May 2018
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olanzapine in chemotherapy-induced nausea and vomiting (CINV), sponsored by N.N. Blokhin Russian Cancer Research Center. Status: unknown.
02
Drugs
olanzapine
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT03478605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03478605.